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RAPID COMMUNICATIONS
Glycerol induced ARF in rats is mediated by tumor necrosis
factor- a
LESTER M. SHULMAN, YAEL YUHAS, INA FROLKIS, SLAVA GAVENDO, AARON KNECHT,
and HASKEL E. ELIAHOU
Nephrology Department, Chaim Sheba Medical Center, Tel Hashomer, Israel
Glycerol induced ARF in rats is mediated by tumor necrosis factor-a.
Glycerol-induced acute renal failure (ARF) in rats is a model of acute
trauma in which intra-muscular injection of 50% glycerol causes rapid
myoglobinuria, oliguria, and a rapid reduction in glomerular filtration
rate. We found that plasma tumor necrosis factor-alpha (TNF-a) is
rapidly induced in glycerol injected rats. It can be detected in some
animals as early as 30 minutes post-injection, peaks at one hour (range:
4 to 32 U/mI) with no significant difference between blood from renal
vein and vena cava, and decreases by three hours. None was detected
in control saline injected rats (P < 0.001). Four out of five rats infused
with neutralizing anti-TNF-a antiserum (200 pit300 g body wt) imme-
diately prior to glycerol injection had significantly protected kidney
function (P = 0.001). In these rats, plasma urea (104.8 58.9 mg%) and
creatinine (1.16 0.38 mg%) were lower and creatinine clearance
higher (0,34 Oil ml/min) than in glycerol injected animals pretreated
with normal serum (291.8 41.8 mg%, 3.15 0.74 mg%, and 0.03
0.03mI/mm, respectively) or animals injected with glycerol alone (302.6
76.8 mg%, 3.45 0.97 mg%, and 0.03 0.03 mI/mm, respectively).
These results imply a direct role for TNF-a in pathogenesis of glycerol
induced ARF in rats.
Tumor necrosis factor-alpha (TNF-a), originally identified by
its anti-tumor activities in vivo and its cytotoxicity against some
tumor cells in vitro, is regarded today as a multifunctional
cytokine affecting many diverse immunological, physiological,
and metabolic functions [1]. TNF-a, one of the major mediators
of inflammation, amplifies its action by stimulating the produc-
tion of other inflammatory cytokines, such as IL-i and IL-6 [1,
2]. It also stimulates production of platelet activating factor
(PAF) and induction of cell adhesion molecules, which in turn
trap other cytokine producing cells [3—7].
TNF-a has been implicated in pathogenesis of chronic kidney
disease. In vivo, TNF-a accelerates progression of kidney
disease and increases mortality rates in mice with lupus nephri-
tis [81, and induces glomerular injury in nephrotic serum nephri-
tis [9] and in acute aminonucleoside nephrosis [10]. Although
TNF-a is produced systemically, mainly by activated macro-
phages, it may also be produced locally in the kidney by
mesangial and tubular epithelial cells [11, 12]. The ability of
exogenously added TNF-a to cause glomerular damage in
Received for publication January 11, 1993
and in revised form March 15, 1993
Accepted for publication March 15, 1993
© 1993 by the International Society of Nephrology
rabbits [13] in vivo or morphological changes and cytotoxic
damage to glomerular mesangial cells in vitro [14, 15] indicated
that it might also play a role in acute renal failure.
We report here that TNF-a is directly involved in pathogen-
esis of acute renal failure (ARF) in rats. We used a model
system in which intra-muscular administration of 50% glycerol
causes rapid myoglobinuria, oliguria, and a reduction of renal
blood flow. This model resembles rhabdomyolysis and cases of
muscle crush syndrome with renal involvement [16—19].
Methods
LAL-endotoxin assay
Limulus amebocyte lysate (LAL assay, Assoc. of Cape Cod,
mc, Woods Hole, Massachusetts, USA) sensitive to 0.065 U/ml
endotoxin was used according to the manufacturer's specifica-
tions to test all solutions used for injection into rats. Only
solutions below 0.065 U/ml were used.
Animals and experimental treatment
Hydropenic (18 hrs withdrawal of drinking water), male
Sprague-Dawley rats weighing between 250 and 350 grams were
anesthetized with ether and injected intra-muscularly with 10
mLlkg of 50% glycerol in water (wt/vol) distributed equally in
both hind limbs. Saline (0.9%) was substituted for 50% glycerol
in control animals. Both solutions were sterile and endotoxin
free (< 0.063 U/ml) as determined by LAL assay.
Group I animals. Laparotomy was performed on Group I
animals maintained under ether anesthesia and continuously
monitored using a non-invasive ITTC rat tail, blood pressure
monitoring system (ITT Corporation, Woodlane Hills, Califor-
nia, USA). Samples of whole blood (1.0 ml) were obtained
directly from the vena cava immediately before injection and
one hour following injection. A separate sample of renal vein
blood (1.0 ml) was obtained one hour post-injection. Alterna-
tively, in some animals, the second sample was taken at either
30 minutes or three hours post-injection.
Group II animals. Laparotomy and the second blood sample
were omitted in Group II animals. Instead, immediately before
injection, whole blood (0.5 ml) was obtained from a P50
catheter inserted via the femoral vein into the inferior vena
cava. Some Group II rats received i.v. infusion of either normal
rabbit serum or rabbit neutralizing anti-TNF-a antisera (Gen-
zyme, Cambridge, Massachusetts, USA; 200 41300 g body wt)
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Fig. 1. TNF-a (U/mi) after intra-muscular
injection of 50% glycerol or saline. Circulating
TNF-a concentrations after intra muscular
injection of 50% glycerol (•) or saline (0).
Plasma TNF-a (U/mi) concentrations were
determined from blood samples obtained from
the vena cava before treatment (0), and one
hour (1) and 24 hours (24) after injection for
Group I animals as described in the Methods.
The plasma TNF-a concentration was also
determined for blood taken from the renal
vein one hour after injection. Horizontal bars
represent the mean TNF-a concentration. The
appearance of TNF-n at one hour in glycerol
injected rats was significant (P < 0.001,
unpaired Student's t-test), whereas the
difference between concentrations in vena
cava and the renal vein of these animals was
not (P > 0.2, paired Student's t-test).
immediately before intra-muscular injection of the 50% glycerol
(wt/vol). All Group I and II rats had free access to water and
were maintained in metabolic cages 24 hours post-glycerol or
saline injection for quantitative urine collection.
Each blood sample was immediately introduced into a
chilled, heparinized test tube and centrifuged in the cold for
eight minutes at 2000 rpm to obtain plasma for TNF-a determi-
nation. After each blood sample, all rats were immediately
rehydrated with an equivalent volume of saline. In addition,
rats in Group I were rehydrated with 4 ml saline over a 30
minute interval after the second plasma sample was taken. At
24 hours, all Group I and II animals were re-anesthetized and a
further blood sample was obtained directly from the vena cava.
Creatinine and urea measurements and creatinine clearance
calculation
Creatinine was measured in plasma and urine by a spectro-
photometric kinetic method (Jaffè reaction). Plasma urea was
measured spectrophotometrically using a Uree Cinetique UV
250 Kit (bioMerieux, Charbonnieres-les-Bains, France).
TNF-a determinations
Plasma for TNF-a assay was stored at —70°C until assay.
TNF-a levels were determined on the basis of cytotoxic activity
assay on mouse L929 cells according to the method of Yuhas et
al [20]. Each assay included a standard curve of recombinant
human TNF-a (specific activity 6 X 106 IU/0.4 ml, 0.5 mglml)
provided by Dr. D. Wallach (Weizmann Institute, Rehovot,
Israel). The limit of detection was 1 U/ml.
Antisera
Rabbit neutralizing anti-murine TNF-a antisera was pur-
chased from Genzyme (specific activity; 1 l neutralizes 1000
U/ml mouse TNF-a). Normal rabbit serum (NRS) served as
control. We determined that 1 d of the anti-munne TNF-a
antisera was sufficient to neutralize 150 U/ml of rat plasma
TNF-a by preincubating serial dilutions of the antisera with 10
and 30 U/ml rat plasma TNF-cs and quantitating the inhibition of
cytotoxicity on L929 cells.
Statistics
Significance of experimental results between animals was
evaluated using the unpaired Student's t-test. Paired Student's
t-test was used to evaluate differences between TNF-a values in
renal vein versus vena cava within the same animals.
Results
Correlation of increased TNF-cs with glycerol induced ARF
Plasma TNF-a levels were determined in Group I animals at
0, 1 hour and 24 hours after glycerol or saline administration as
described in Methods. Six of eight experimental rats had detect-
able circulating TNF-a one hour after i.m. glycerol (Fig. 1). In
contrast there was no TNF-a at one hour in six of six control
animals (P < 0.001). None of the control or experimental
animals had plasma TNF-a at 0 or 24 hours. Release of TNF-a
is rapid since TNF-a was already present in some animals as
early as 30 minutes post-injection. Of two animals tested at this
time point, one had a titer of 12 U/ml in blood from the vena
cava, while there was no detectable TNF in the other. By three
hours, TNF levels dropped relative to the mean at one hour.
Blood from the vena cava of two animals tested had 4 and 12
U/mI. The difference in mean TNF-cs between renal vein and
vena cava in glycerol injected animals at one hour was not
significant (paired Student's t-test, P > 0.2). All cytotoxic
activity was neutralized by preincubation with rabbit anti-
murine TNF-a antisera, confirming that the cytotoxic activity
was due to TNF-a (not shown).
All glycerol injected animals developed severe ARF as shown
by elevation of blood levels of urea and creatinine and severe
reduction of creatinine clearance (Fig. 2A, B and C, respective-
ly).
Pre-administration of anti-TNF-a antisera provides
sign(ficant protection against development of glycerol
induced ARF
Group II rats injected with glycerol but not pretreated with
anti-TNF-a antiserum or normal serum (N = 9) developed ARF
to a similar extent as glycerol injected Group I rats (Fig. 2).
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Fig. 2. Protection against development of glycerol-induced ARF in rats pretreated with anti-TNF-a antisera. Plasma urea (A) and plasma
creatinine (B) concentrations were determined for Group I rats (stippled bars ) and Group II rats (hatched bars ) at 24 hours post-injection as
described in the Methods. These values and pre-injection baseline values [baseline (a), baseline (b), respectively] are expressed in mg% SD.
Group I animals were injected with either saline [saline (a)] or 50% glycerol [glycerol (a)]. Group II animals were injected with glycerol [glycerol
(b)] or injected with glycerol immediately after pretreatment with normal rabbit serum [glycerol (b) NRS] or rabbit anti-TNF-cr antiserum [glycerol
(b) anti-TNF Ab]. Creatinine clearances over 24 hours (C) for the animals in A and B are in mI/mm SD. For data presented in A, B, and C,
differences between Group II anti-TNF-a pretreated, glycerol injected animals and both Group II glycerol injected and Group II NRS pretreated,
glycerol injected animals were highly significant (P = 0.001).Differences between Group I glycerol injected and Group II glycerol injected or Group
II NRS pretreated, glycerol injected animals were not significant (P> 0.25).
Kidney dysfunction was ameliorated in four of five Group II
animals that received intravenous anti-TNF-a antiserum (200
p11300 g body wt) immediately prior to intra-muscular glycerol
injection. These four animals had significantly lower plasma
urea (P = 0.001), lower plasma creatinine (P = 0.001), and
higher creatinine clearance (P 0.001) than experimental
Group II animals that received normal rabbit serum (N = 7) or
did not receive any rabbit serum (N = 9; Fig. 2). This difference
is still highly significant when data from all five rats are
analyzed, such as, P 0.01 instead of 0.001 for plasma urea, P
= 0.005 instead of 0.001 for serum creatinine, and P = 0.02
instead of 0.001 for creatinine clearance. Differences between
experimental Group II animals that received normal rabbit
serum or did not receive any rabbit serum were not significant
(P > 0.6).
Discussion
The glycerol induced model of ARF in rats is a well estab-
lished model of acute trauma [16, 17, 19, 20]. Intra-muscular
injection of 50% glycerol causes rapid myoglobinuria, oliguria,
and a rapid reduction in glomerular filtration rate. Although the
pathophysiology of this model is not yet completely under-
stood, there is evidence that the decrease in renal blood flow
and ischemia are responsible for kidney damage [17, 211. Our
results demonstrate that TNF-a is rapidly induced in glycerol
injected rats and that administration of neutralizing anti-TNF-a
antiserum immediately prior to glycerol injection protects kid-
ney function, that is plasma urea and creatinine were signifi-
cantly lower and creatinine clearance significantly higher (P
0.001). In contrast, the severity of ARF in glycerol injected
animals pretreated with normal serum was indistinguishable
from that of animals injected with glycerol alone (P > 0.6).
TNF-a has already been implicated in the pathogenesis of
several types of nephrotic syndrome, such as acute aminonu-
cleoside nephrosis, nephrotic serum nephritis (antibody-medi-
ated glomerular injury), and lupus [8—10, 22]. These, however,
are chronic diseases where kidney dysfunction and damage
accumulates over time. We have shown here that endogenously
produced TNF-a plays a major role in induction of acute renal
failure. Interestingly, ARF is also one of the main syndromes in
septic shock during which TNF-a is extensively released.
Furthermore, the kinetics of appearance of TNF-a in response
to LPS [23], comprising a rapid rise, peaking one hour and
decreasing by five hours post-injection of inducer, is similar to
that seen in response to endotoxin-free glycerol injection.
There are several ways that TNF-cs may mediate alteration in
kidney function. It acts on vascular endothelium, altering its
permeability [24], inducing synthesis of coagulation factors
[25], and increasing expression of adhesion molecules [5—71.
Recently, Linas et al [26], reported that addition of activated
PMN to mildly ischemic kidney, but not to non-ischemic
kidney, caused severe renal injury. Cytotoxic products of
neutrophils have been shown to contribute to ischemic-reper-
fusion injury in a number of tissues [27, 281. A parallel combi-
nation of mild ischemia and polymorphonuclear cells activated
by released TNF-a [29] may exist in our model system. The
TNF-a-induced expression of leukocyte adhesion molecules on
endothelial cells can increase the duration and augment the
extent of damage by recruiting and trapping neutrophils and
cells secreting TNF-a, IL-l, IL-6, and other soluble mediators.
In addition, TNF-a is an inducer of arachidonic acid metabo-
lites such as platelet activating factor, prostaglandin E2, and
thromboxane A2 which have also been implicated in kidney
diseases [3, 30, 311. Acute renal failure has been induced in rats
by injecting PAF [32]. Moreover, ARF has been prevented in
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ischemic [32, 33], glycerol induced [17], and cytotoxic (cis-
diamine dichloro platinum) [34, 35]rat ARF model systems by
the use of specific inhibitors of PAF action. There is also
evidence that PAF may be involved in up-regulation of TNF-a
release [36]. Thus, PAP production and entrapment of cytokine
secreting cells by up-regulation of adhesion molecules may be
part of an autocrine loop resulting in increased levels of TNF-a.
TNF-a treatment of glomerular mesangial cells in vitro caused
contraction, alteration in their cytoskeleton, and cytolysis [14,
15]. Thus it is also possible that it might directly effect these
cells in vivo.
The identity and location of cells secreting TNF-a and the
mechanism by which glycerol triggers TNF-a release have yet
to be determined. To our knowledge this is the first time that
TNF-a has been shown to be released in response to glycerol or
glycerol induced damage.
In conclusion, pretreatment with neutralizing anti-TNF-a
antisera significantly ameliorates renal function in rats in which
ARF has been induced by glycerol injection. This together with
the correlation of detectable levels of circulating TNF-s 30 to 60
minutes after injection of glycerol but not saline argues strongly
for the direct involvement of TNF-a in the pathogenesis of
acute renal failure.
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